Azenta, Inc. $AZTA Holdings Cut by Royal Bank of Canada

Royal Bank of Canada reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 5.2% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 494,469 shares of the company’s stock after selling 27,260 shares during the period. Royal Bank of Canada owned 1.07% of Azenta worth $10,449,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Azenta by 2,067.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after purchasing an additional 765 shares during the last quarter. Assetmark Inc. boosted its position in Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock valued at $28,000 after purchasing an additional 292 shares during the period. State of Wyoming bought a new position in Azenta during the 1st quarter worth $38,000. Osaic Holdings Inc. grew its stake in Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after buying an additional 385 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in Azenta by 98.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock worth $46,000 after buying an additional 689 shares during the period. 99.08% of the stock is owned by institutional investors.

Azenta Price Performance

NASDAQ AZTA opened at $32.04 on Friday. Azenta, Inc. has a 12 month low of $15.93 and a 12 month high of $41.73. The firm has a market capitalization of $1.48 billion, a PE ratio of -11.61 and a beta of 1.37. The company’s 50 day simple moving average is $25.62 and its 200 day simple moving average is $25.53.

Azenta (NASDAQ:AZTA) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.11 by $0.05. The firm had revenue of $161.18 million for the quarter, compared to analysts’ expectations of $149.31 million. Azenta had a positive return on equity of 1.18% and a negative net margin of 20.63%.

Analysts Set New Price Targets

A number of research firms have issued reports on AZTA. Needham & Company LLC raised their target price on Azenta from $33.00 to $37.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings upgraded shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $41.20.

Azenta Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end?to?end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next?generation sequencing (NGS), DNA synthesis, and molecular biology services.